CTKB Cytek Biosciences (CTKB) Insider Trading, Ownership & Congress Trades
Medical Devices · Laboratory analytical instruments · CIK 0001831915
Form 144 · 1
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
75
13F, latest reported quarter
Conversions, 180 days
39
Codes C/M, not in net · no price filed
What the filings say about CTKB
Planned sales (Form 144), 90 days
$146.5K
1 notice
Cytek Biosciences insider trades (Form 4)
Form 4 buys and sells (codes P and S). Grants, option exercises
and conversions excluded.
No insider purchases or sales are on record for Cytek Biosciences, Inc. in the period covered. Source: SEC Form 4 filings, as of 2026-10-28.
Insider
Filed
Shares
Value
Since filing
Context
- First Form 4 purchase or sale (code P or S) here by this insider on our record.
- The trade is 62.8% of the 55,746 shares held after it.
- No other insider bought within 30 days.
- 75 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Financial Officer McCombe William D. bought about $97.3K of CTKB on Jun 2, 2025, the largest insider purchase at the company since 2022; 75 funds added in the latest 13F quarter.Context
- 32 earlier Form 4 trades (code P or S) here by this insider (32 sales), the last on Apr 9, 2024.
- The trade is 0.3% of the 5,988,502 shares held after it.
- No other insider sold within 30 days.
- 75 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: CHIEF TECHNOLOGY OFFICER Yan Ming sold about $117.4K of CTKB on Apr 19, 2024; 75 funds added in the latest 13F quarter.Context
- 30 earlier Form 4 trades (code P or S) here by this insider (30 sales), the last on Mar 19, 2024.
- The trade is 0.0% of the 6,008,502 shares held after it.
- No other insider sold within 30 days.
- 75 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: CHIEF TECHNOLOGY OFFICER Yan Ming sold about $2.8K of CTKB on Apr 9, 2024; 75 funds added in the latest 13F quarter.Context
- 30 earlier Form 4 trades (code P or S) here by this insider (30 sales), the last on Mar 19, 2024.
- The trade is 0.0% of the 6,008,902 shares held after it.
- No other insider sold within 30 days.
- 75 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: CHIEF TECHNOLOGY OFFICER Yan Ming sold about $10.5K of CTKB on Apr 9, 2024; 75 funds added in the latest 13F quarter.Context
- 29 earlier Form 4 trades (code P or S) here by this insider (29 sales), the last on Mar 18, 2024.
- The trade is 0.3% of the 6,010,402 shares held after it.
- No other insider sold within 30 days.
- 75 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: CHIEF TECHNOLOGY OFFICER Yan Ming sold about $134.2K of CTKB on Mar 19, 2024; 75 funds added in the latest 13F quarter.102 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
Seven facts, ranked against the sector ·
Rank is not a forecast
Insiders
no insider buys or sells on file
Congress
no House purchase disclosed in the last 12 months
Funds
75 funds bought in last quarter
more than 55% of Medical Devices
Revenue
+0.5% year over year
below 77% of Medical Devices
Margin
-33.0% net margin
below 61% of Medical Devices
Buybacks
$80.8M repurchased, FY to 2025-12-31
more than 58% of Medical Devices
Short interest
5.1% of the float short (float per yahoo 2026-10-26) · 3.1 days to cover · settled 2026-09-30
more than 55% of Medical Devices
What changed in the last 30 days
Nothing new filed in the last 30 days
Watch CTKB
A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.
The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
+41.6%12M
Form 144 (planned sale)
Indexed to 100, dividend-adjusted, not a price chart.
When a name files heavily, the largest trades are drawn first.
Who owns CTKB: institutional holders (13F)
13F holdings, latest reported quarter
9,578,643 sh
$42.4M
9,338,010 sh
$41.4M
7,660,943 sh
$33.9M
6,657,030 sh
$29.5M
6,283,450 sh
$27.8M
Congress trades in CTKB
No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.
Activist and 5% holders (13D/13G)
No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.
CTKB planned insider sales (Form 144)
Notice of intent to sell, filed before any sale
PHILIPPE BUSQUE
Filed 2026-09-02
$146.5K
CTKB mutual fund holders (N-PORT)
Funds ranked by the share of their own portfolio in this stock (N-PORT).
WPG Partners Select Small Cap Value Fund
$4.0M position · as of 2026-05-31
1.7%
Royce Capital Fund - Micro-Cap Portfolio
$836.5K position · as of 2026-06-30
0.6%
Royce Micro-Cap Fund
$2.5M position · as of 2026-06-30
0.6%
Dunham Small Cap Value Fund
$542.1K position · as of 2026-07-31
0.6%
Column Small Cap Select Fund
$10.0M position · as of 2026-05-31
0.5%
Invesco S&P SmallCap Health Care ETF
$322.7K position · as of 2026-05-31
0.2%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M ·
% is the share of the fund's own portfolio
Executive pay vs shareholder return · Wenbin Jiang, Ph.D
CEO pay, headline and as actually paid, against the company's
return and its chosen peers' (DEF 14A).
FY
CEO total
Actually paid
Other execs, avg
TSR
Peer TSR
2023
$4.9M
$3.7M
$2.0M
-51%
-14%
2022
$3.9M
$1.9M
$1.4M
-46%
-18%
2021
$4.8M
-$130.5K
$2.6M
-13%
-9%
Tagged by the company under SEC Item 402(v). Returns are
cumulative from the start of the disclosure period. Green where the company beat its own peer group.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
Insiders have filed to sell, before selling.
The record shows 75 funds added last quarter, $146.5K in planned Form 144 sales. Each figure is a federal filing, dated the day it went public.
CTKB financials
Revenue growth
+0.5%
XBRL, annual
Net margin
-33.0%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$206.7M
four quarters, 2025-07-01 to 2026-06-30
Revenue, TTM CTKB
| FY Dec 2025 | $201.5M |
| FY Dec 2024 | $200.5M |
| FY Dec 2023 | $193.0M |
| FY Dec 2022 | $164.0M |
| FY Dec 2021 | $128.0M |
| Jun 2026 | $48.1M |
| Mar 2026 | $44.1M |
| Dec 2025 | $62.1M |
| Sep 2025 | $52.3M |
| Jun 2025 | $45.6M |
| Mar 2025 | $41.5M |
| Dec 2024 | $57.5M |
| Sep 2024 | $51.5M |
At each fiscal year end
Single quarter
Net margin, TTM
-39.0%
net income over revenue, 2025-07-01 to 2026-06-30
Net margin, TTM CTKB
| FY Dec 2025 | -33.0% |
| FY Dec 2024 | -3.0% |
| FY Dec 2023 | -6.3% |
| FY Dec 2022 | +1.5% |
| FY Dec 2021 | +2.4% |
| Jun 2026 | -25.3% |
| Mar 2026 | -42.7% |
| Dec 2025 | -70.9% |
| Sep 2025 | -10.5% |
| Jun 2025 | -12.2% |
| Mar 2025 | -27.5% |
| Dec 2024 | +16.8% |
| Sep 2024 | +1.8% |
At each fiscal year end
Single quarter
Free cash flow, TTM
-$12.1M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Free cash flow, TTM CTKB
| FY Dec 2025 | -$8.8M |
| FY Dec 2024 | $21.9M |
| FY Dec 2023 | $633.0K |
| FY Dec 2022 | -$22.0M |
| FY Dec 2021 | $266.0K |
| Jun 2026 | -$849.0K |
| Mar 2026 | -$4.9M |
| Dec 2025 | -$1.8M |
| Sep 2025 | -$4.6M |
| Jun 2025 | -$1.5M |
| Mar 2025 | -$974.0K |
| Dec 2024 | $1.1M |
| Sep 2024 | $12.2M |
At each fiscal year end
Single quarter
Debt to equity
n/a
no debt line filed
Debt to equity CTKB
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Cash flow to debt
n/a
no debt line filed
Cash flow to debt CTKB
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on equity
-23.0%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on equity CTKB
| FY Dec 2025 | -18.0% |
| FY Dec 2024 | -1.5% |
| FY Dec 2023 | -3.0% |
| FY Dec 2022 | +0.6% |
| FY Dec 2021 | +1.6% |
| Jun 2026 | -23.0% |
| Mar 2026 | -20.9% |
| Dec 2025 | -18.0% |
| Sep 2025 | -3.4% |
| Jun 2025 | -1.7% |
| Mar 2025 | -2.9% |
| Dec 2024 | -1.5% |
| Sep 2024 | -2.5% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on assets
-17.1%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets CTKB
| FY Dec 2025 | -13.8% |
| FY Dec 2024 | -1.2% |
| FY Dec 2023 | -2.4% |
| FY Dec 2022 | +0.5% |
| FY Dec 2021 | +0.9% |
| Jun 2026 | -17.1% |
| Mar 2026 | -15.9% |
| Dec 2025 | -13.8% |
| Sep 2025 | -2.6% |
| Jun 2025 | -1.3% |
| Mar 2025 | -2.3% |
| Dec 2024 | -1.2% |
| Sep 2024 | -2.0% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on invested capital
n/a
pre-tax loss, no effective tax rate to apply
Return on invested capital CTKB
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on capital employed
-11.4%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
Return on capital employed CTKB
| FY Dec 2025 | -9.9% |
| FY Dec 2024 | -4.7% |
| FY Dec 2023 | -6.1% |
| FY Dec 2022 | -0.4% |
| FY Dec 2021 | +2.9% |
| Jun 2026 | -11.4% |
| Mar 2026 | -11.2% |
| Dec 2025 | -9.9% |
| Sep 2025 | -7.5% |
| Jun 2025 | -6.3% |
| Mar 2025 | -5.8% |
| Dec 2024 | -4.7% |
| Sep 2024 | -5.3% |
At each fiscal year end
Trailing four quarters at each quarter end
P/E, trailing
147.25x
close 2026-10-26 over four quarters of diluted EPS, 2022-01-01 to 2022-12-31
P/E, trailing CTKB
| FY Dec 2025 | 126.25x |
| FY Dec 2024 | 162.25x |
| FY Dec 2023 | 228.00x |
| FY Dec 2022 | 255.25x |
| FY Dec 2021 | n/a |
| Jun 2026 | 110.75x |
| Mar 2026 | 109.25x |
| Dec 2025 | 126.25x |
| Sep 2025 | 86.75x |
| Jun 2025 | 85.00x |
| Mar 2025 | 100.25x |
| Dec 2024 | 162.25x |
| Sep 2024 | 138.50x |
At each fiscal year end
Trailing four quarters at each quarter end
Enterprise value
n/a
no debt line filed
Enterprise value CTKB
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
FCF yield
-1.6%
TTM free cash flow over market value at close 2026-10-26
FCF yield CTKB
| FY Dec 2025 | -1.4% |
| FY Dec 2024 | +2.6% |
| FY Dec 2023 | +0.1% |
| FY Dec 2022 | -1.6% |
| FY Dec 2021 | +0.0% |
| Jun 2026 | -2.1% |
| Mar 2026 | -2.3% |
| Dec 2025 | -1.4% |
| Sep 2025 | -1.3% |
| Jun 2025 | +2.5% |
| Mar 2025 | +3.4% |
| Dec 2024 | +2.6% |
| Sep 2024 | +3.9% |
At each fiscal year end
Trailing four quarters at each quarter end
PEG, trailing
n/a
prior-year trailing EPS was a loss, growth undefined
PEG, trailing CTKB
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Price as of 2026-10-26. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
| 2025-12 | 2024-12 | 2023-12 | 2022-12 | |
|---|---|---|---|---|
| Revenue | $201.5M | $200.5M | $193.0M | $164.0M |
| Gross profit | $104.5M | $111.1M | $109.4M | $101.0M |
| Operating income | -$40.4M | -$20.5M | -$27.8M | -$1.8M |
| Net income | -$66.5M | -$6.0M | -$12.1M | $2.5M |
| EPS (diluted) | n/a | n/a | -0.09 | 0.02 |
| Operating cash flow | -$4.7M | $25.4M | $5.3M | -$12.2M |
| Cash | $90.9M | $98.7M | $167.3M | $296.6M |
| Buybacks | $15.1M | $21.6M | $44.2M | $0 |
SEC XBRL, fiscal years, as known on 2026-10-28
CTKB Stock Sonar score 4/7 axes
Find similar shapesCompareCTKB ranks highest on risk and compliance (68th percentile) and institutional and government (55th), and lowest on growth (36th), among Medical Devices peers.
4 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored
CTKB filings, in plain words
Are there planned insider sales of CTKB?
Yes. 1 Form 144 notice of planned insider sales was filed in the 90 days to 2026-10-28, covering $146.5K of stock; the latest, by PHILIPPE BUSQUE, was filed 2026-09-02.
Read the full summary
Insiders filed 1 Form 144 notice of intent to sell in the 90 days to 2026-10-28, covering $146.5K of stock. Each figure is counted from SEC and House filings as of 2026-10-28, dated the day the filing was made public.
Explore insider trading and ownership data
Every company we track, ranked by each kind of filing
